Fosamax Jaw Damage Trial Will Not Result in Punitive Damages

According to a pretrial order, Merck & Co. will not face the possibility of punitive damages in the first Fosamax trial scheduled to begin next month in New York. The case involves allegations that the drug maker failed to warn that their popular osteoporosis drug Fosamax increases the risk of debilitating jaw damage, known as jaw necrosis or osteonecrosis of the jaw (ONJ).

U.S. District Judge John Keenan, who is presiding over the consolidated federal Fosamax litigation in Southern District of New York, announced this week that the first of three “bellwether” cases set for trial to start August 11 will go forward as planned, as Merck’s motion to have the case dismissed on liability was denied. However, Bloomberg News reports that Judge Keenan indicated that the jury will not be able to consider the possibility of punitive damages as a result of Merck’s action, even if they find for the plaintiff.

The Fosamax lawsuit involves a claim filed by plaintiff Shirley Boles, who alleges that she developed permanent jaw damage as a result of using Merck’s drug from January 1997 to March 2006. The case is one of more than 850 lawsuits pending against Merck over the alleged Fosamax jaw damage, with about 700 of the cases pending in a federal MDL, or Multidistrict Litigation, before Judge Keenan.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Fosamax (alendronate sodium), is a member of a class of drugs known as bisphosphonates. Approved by the FDA in October 1995, it generated more than $3 billion in sales annually for Merck before it became available as a generic last year and more than 20 million people have used the drug.

The Fosamax jaw damage lawsuits allege that Merck failed to adequately warn about the risk of osteonecrosis of the jaw and made false and misleading misrepresentations about the drug’s safety, preventing patients and doctors from avoiding the painful and potentially disfiguring condition.

Osteonecrosis of the jaw symptoms can cause swelling or infection of the gums, loose teeth or tooth aches, pain in the jaw and exposed areas of bone inside the mouth. There is no cure or effective treatment for the painful and debilitating condition, and many people who suffer from jaw necrosis ultimately require surgery to remove portions of their jaw.

Judge Keenan’s rulings clear the way for jury selection and opening statements to begin on August 11. If Merck is found liable for Boles jaw damage, the jury will only be able to award compensatory damages.

Following the Boles case, a second trial is scheduled to begin on December 1, 2009 for plaintiff Bessie Fleming, and a third filed by Karen Greene is scheduled to begin January 11, 2010.

In addition to the federal MDL cases, there are about 130 state cases consolidated before Judge Carol Higbee in New Jersey.

Image Credit: |

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.